1.Effect of the Mixture of Thrombin Powder and Gelfoam Powder on Control of Exposed Cancellous Bone Bleeding.
Sung Wan PARK ; Ha Young CHO ; Seung Myoung LEE ; Seong Hun JEONG ; Jin Kyu SONG ; Suk Jung JANG ; Ho SHIN
Journal of Korean Neurosurgical Society 2000;29(5):664-667
No abstract available.
Gelatin Sponge, Absorbable*
;
Hemorrhage*
;
Thrombin*
2.A Case of Successful Treatment of Femoral Artery Pseudoaneurysm Using Thrombin Injection.
Nam Sik YOON ; Sun Ho HWANG ; Kye Hun KIM ; Jong Chun PARK ; Jung Chae KANG ; Ock Kyu PARK
Journal of Cardiovascular Ultrasound 2008;16(2):66-67
No abstract available.
Aneurysm, False
;
Femoral Artery
;
Thrombin
3.A clinical study of donor site care in the split thickness skin graft with thrombin application.
Kang Won LEE ; Hong Mi YOUCK ; Chin Ho YOON ; Han Joong KIM
Journal of the Korean Society of Plastic and Reconstructive Surgeons 1991;18(3):528-532
No abstract available.
Humans
;
Skin*
;
Thrombin*
;
Tissue Donors*
;
Transplants*
4.Argatroban Treatment in Acute Ischemic Stroke: Multicenter, Randomized, Aspirin-Controlled Study.
Young Mok SONG ; Sang Wuk JEONG ; Hee Jun BAE ; Byung Woo YOON ; Ki Hyun CHO ; Byung Chul LEE ; Yong Seok LEE ; Jong Sung KIM ; Si Ryung HAN ; Kyung Moo YOO ; Jae Kyu ROH
Journal of the Korean Neurological Association 2004;22(4):302-309
BACKGROUND: Argatroban, a direct thrombin inhibitor, has been suggested to be beneficial in acute ischemic stroke by preventing microthrombi formation. The aim of this multicenter, aspirin-controlled, randomized trial is to determine the safety and the efficacy of argatroban compared with aspirin in acute ischemic stroke. METHODS: The patients within 48 hours of noncardioembolic ischemic stroke were recruited from 8 centers. Argatroban was infused continuously at 2.5 mg/hr for the first 48 h, and then 10mg of argatroban was infused over 3 h twice a day on days 3-7. Control group received aspirin 300 mg/day for 7 days. The primary outcome was the NIHSS at 30 days and the secondary outcome was Barthel index (BI) and modified Rankin scale (mRS) at 90 days. The safety was evaluated by the incidence of bleeding complication. RESULTS: A total of 236 patients (123 for argatroban and 113 for aspirin) were included. NIHSS at 30 days, BI at 90 days and mRS at 90 days did not show significant difference between the argatroban and the aspirin group (3.1 +/- 3.1 vs 3.5 +/- 3.0, 88.9 +/- 22.5 vs 86.2 +/- 23.8, 1.4 +/- 1.1 vs 1.6 +/- 1.3, p>0.3, respectively). Post hoc analysis revealed that as for the patients who were treated within 24 hours after onset, numbers of patients with NIHSS=1 at 30 days were larger in the argatroban group (23 of 49) than in the aspirin group (10 of 40) (p=0.03). Bleeding complication was not different between the two groups (2 of 123 vs 0 of 113: p>0.4). CONCLUSIONS: Argatroban treatment is relatively safe in acute ischemic stroke. The efficacy of argatroban is not superior to aspirin. However, argatroban may be more beneficial in some subgroup of stroke patients than aspirin.
Aspirin
;
Hemorrhage
;
Humans
;
Incidence
;
Stroke*
;
Thrombin
5.Open Treatment of the Split-Thickness Skin Donor Site
The Journal of the Korean Orthopaedic Association 1972;7(1):93-95
Fiften patients had their split-thickness skin-donor sites treated open using topical thrombin solution. This technique was more convenient compared with commonly using compression dressing technique. Application of topical thrombin solution to the donor sites quickly provided complete hemostasis and became dry within forty-eight hours. Thereafter an almost pain-free donor site and uncomplicated healing was followed in all cases. The two cardinal advantages of this treatment are thought to be followings; 1) It markedly reduces the period of discomfort from the donor site. 2) It encourages rapid, uncomplicated healing of the donor site.
Bandages
;
Hemostasis
;
Humans
;
Skin
;
Thrombin
;
Tissue Donors
6.Thrombin and tumor metastasis - review.
Yu-Hong MENG ; Ji-Yao YU ; Ying-Lin LU
Journal of Experimental Hematology 2007;15(3):671-674
Thrombin is a multifunctional serine protease that plays a key role in a variety of physiological and pathological conditions. In addition to the role in hemostasis and coagulation, thrombin has other numerous biological activities affecting inflammation, immune responses, tissue repair and wound healing. Apart from its physiological role thrombin activates the oncogenic potential of both normal and malignant cells and leads a metastatic phenotype. It is a potent mitogen for many tumor cells. It potentiates the proliferative response of tumor cells to some growth factors, increases the adhesive properties to the platelets and invasion processes of tumor cells to the extracellular matrix, enhances the metastatic capacity of tumor cells, activates angiogenesis and remodels the microenvironment of the tumor. The cellular biological effects of thrombin are mediated at least in part by a new subfamily of G-protein-coupled receptors designated proteinase-activited receptors (PARs). Thrombin has a bilateral effect on tumor cells:enhanced growth at low concentration, impaired growth/apoptosis at higher concentration. In this papers, the biological function of thrombin, thrombin and tumors, and thrombin receptors etc were reviewed.
Animals
;
Humans
;
Neoplasm Invasiveness
;
Neoplasm Metastasis
;
Neoplasms
;
enzymology
;
pathology
;
Receptors, Thrombin
;
physiology
;
Thrombin
;
physiology
7.Expression of antisense thrombin receptor gene inhibits intimal hyperplasia of rat carotid artery after balloon injury.
Guofeng REN ; Zongli WANG ; Yongjun LI ; Jing YANG ; Peimao LIU ; Mingpeng SHE
Chinese Journal of Pathology 2002;31(3):231-235
OBJECTIVETo study the mechanism of restenosis after angioplasty and to clarify the effect of thrombin and its receptor on restenosis development.
METHODSBalloon catheter-induced injury was adopted to induce intimal hyperplasia of the carotid arteries in rats. Antisense thrombin receptor (ATR) cDNA was transfected by perfusing recombinant LXSN ATR plasmid/nanoparticle complex into the segment of the injured carotid artery.
RESULTSPCR result showed integration of the recombined gene. Dot blot showed the expression of antisense TR mediated by recombinant LXSN ATR plasmid/nanoparticle complex in the wall of common carotid arteries of the experimental group rats, which enabled to inhibit TR gene expression and intimal hyperplasia of the injured arteries.
CONCLUSIONSThrombin and its receptor play an important role in the formation of neointima after the injury, which provides a potential clue in developing a new approach for prevention and treatment of restenosis after angioplasty.
Animals ; Carotid Arteries ; Hyperplasia ; Rats ; Receptors, Thrombin ; metabolism ; Thrombin ; pharmacology ; Tunica Intima ; metabolism
8.Bactericidal Activity of Thrombin - induced Platelet Microbicidal Protein Against Streptococcus rattus BHT.
Si Young LEE ; Jeong Sook LEE ; Son Jin CHOE
Journal of Bacteriology and Virology 2001;31(4):317-324
No abstract available.
Animals
;
Blood Platelets*
;
Butylated Hydroxytoluene*
;
Rats*
;
Streptococcus*
;
Thrombin*
9.Ultrasound Guided Local Endovascular Coiling of an Iatrogenic Superficial Temporal Artery Pseudoaneurysm.
Christina Huang WRIGHT ; James WRIGHT ; Anish BADJATIYA ; Sunil MANJILA ; Steven REED ; Robert GEERTMAN
Journal of Cerebrovascular and Endovascular Neurosurgery 2015;17(4):313-317
Pseudoaneurysms of the superficial temporal artery are rare and may be treated by manual compression, surgical intervention, coil embolization, or percutaneous thrombin injection. We present a novel technique of local ultrasound guided low-profile coil embolization of the superficial temporal artery with both satisfactory cosmetic and surgical results.
Aneurysm, False*
;
Embolization, Therapeutic
;
Temporal Arteries*
;
Thrombin
;
Ultrasonography*
10.Intraocular Infusate with Hemocoagulase for the Control of Bleeding During Vitreous Surgery.
Ho Sung LEE ; In Taek KIM ; Hyung Jun KIM ; Jin Ho CHO ; Sang Ha KIM
Journal of the Korean Ophthalmological Society 1988;29(2):297-302
The effects of hemocoagulase in injectable form(hemocoagulating enzymatic fraction of South American snake Botrops Jararaca venom provided by Ravizza) on the control of intraocular bleeding during vitreous surgery were evaluated in rabbit eyes. Intraocular infusion solution with hemocoagulase(1 NIH thrombin unit/100 ml BSS) significantly reduced the bleeding time to 33.2 +/- 9.7 seconds. Electroretinogram b-wave and electroretinogram c-wave showed no abnormality. Infusate with hemocoagulase appeared to be a favorite agent for the control of intraocular bleeding during viteous surgery.
Batroxobin*
;
Bleeding Time
;
Bothrops
;
Hemorrhage*
;
Snakes
;
Thrombin
;
Venoms